CN218944126U

CN218944126U - Medicine sacculus pipe

Info

Publication number: CN218944126U
Application number: CN202222597299.6U
Authority: CN
Inventors: 刘朝生; 韦政军; 张志旋; 周友明; 郭新宇; 李琴芳; 林浩
Original assignee: Guangdong Bomai Medical Technology Co Ltd
Current assignee: Guangdong Bomai Medical Technology Co Ltd
Priority date: 2022-09-27
Filing date: 2022-09-27
Publication date: 2023-05-02
Anticipated expiration: 2032-09-27

Abstract

The utility model relates to a drug balloon catheter, comprising: a catheter, a working assembly, and a tip disposed at a distal-most end of the catheter; the working assembly comprises a first working group, a second working group, a third working group and a fourth working group; the second working group comprises a second interface, a second cavity, a first balloon and a fifth balloon, wherein the first balloon and the fifth balloon are used for adhering floating medicines; the third working group comprises a third interface, a third cavity and a third balloon, and the third balloon is loaded with medicine; the fourth working set includes a fourth interface, a fourth lumen, a second balloon, and a fourth balloon, the second balloon and the fourth balloon for providing a temporary enclosed space. The drug balloon catheter can effectively prevent drug loss in the conveying process; the drug release effect is good, the utilization rate of the drug is improved, and the quality of vascular interventional therapy is ensured; the first balloon and the fifth balloon are adhered with the floating medicine and are carried out of the body, so that the risk of blocking the blood vessel by the medicine is reduced.

Description

Medicine sacculus pipe

Technical Field

The utility model relates to the technical field of medical instruments, in particular to a drug balloon catheter.

Background

The balloon catheter with the drug coating is a balloon catheter with the drug coating loaded on the surface of a common bare balloon, after the balloon loaded with the drug is conveyed to a lesion site, the balloon is expanded to expand the vessel wall of the lesion site, so that the blood flow is restored to be smooth, and the drug coating is eluted from the surface of the balloon and released to the vessel wall, so that the proliferation of smooth muscle cells can be further inhibited, and the restenosis of the vessel is prevented. Therefore, the drug-coated balloon catheter not only can be expanded into blood circulation to establish a channel through the balloon, but also can avoid the defects of restenosis, thrombus and the like in the stent after the stent implantation operation.

Prior art drug coated balloon catheters generally use a balloon catheter having a balloon portion to which a drug coating is applied on the outer surface thereof, and then the drug-carrying balloon is delivered to the lesion and then expanded according to the characteristics of the lesion. However, a large number of drug particles are washed by blood and fall into the blood vessel during the pushing process; during the release of the drug, the drug does not adhere completely to the vessel wall, resulting in a small amount of drug floating in the blood. The floating medicine particles in the blood vessel can not be recovered and can not be effectively discharged outside the blood vessel, so that risks such as embolism and the like are easily caused, the metabolic burden of the organism is increased, and the safety of the instrument is reduced.

Disclosure of Invention

Based on the above, the utility model aims to provide a drug balloon catheter which can effectively prevent drug loss in the process of delivery; in the process of drug release, the drug release effect is good, the utilization rate of the drug is improved, and the quality of vascular interventional therapy is ensured; the first balloon and the fifth balloon are used for adhering floating medicines and carrying out the medicines, so that the risk of blocking blood vessels by the medicines is reduced.

The utility model provides a drug balloon catheter, comprising: a catheter, a working assembly, and a tip disposed at a distal-most end of the catheter; the working assembly comprises a first working group, a second working group, a third working group and a fourth working group;

the first working group comprises a first interface and a first cavity; the first interface is disposed at the proximal end of the catheter; the first interface is connected with the first cavity; the first cavity is arranged in the catheter and is used for passing through the guide wire;

the third working group comprises a third interface, a third cavity and a third balloon; the third interface is arranged at the proximal end of the catheter; the third balloon is sleeved outside the catheter; the drug is loaded on the outer surface of the third balloon; one end of the third cavity is connected with the third interface, and the other end of the third cavity is communicated with the third saccule;

the second working group comprises a second interface, a second cavity and a first balloon and a fifth balloon with surfaces coated with adhesive; the second interface is arranged at the proximal end of the catheter; the first balloon and the fifth balloon are respectively arranged at two sides of the third balloon, and the first balloon and the fifth balloon are sleeved outside the catheter; one end of the second cavity is connected with the second interface, and the other end of the second cavity is sequentially communicated with the first balloon and the fifth balloon;

the fourth working group comprises a fourth interface, a fourth cavity, a second balloon and a fourth balloon; the fourth interface is arranged at the proximal end of the catheter; the second balloon and the fourth balloon are sleeved outside the catheter; the second balloon is arranged between the first balloon and the third balloon; the fourth balloon is arranged between the third balloon and the fifth balloon; one end of the fourth cavity is connected with the fourth interface, and the other end of the fourth cavity is sequentially communicated with the second balloon and the fourth balloon;

the first cavity, the second cavity, the third cavity and the fourth cavity are mutually isolated and arranged inside the catheter.

The drug balloon catheter provided by the utility model can effectively prevent drug loss in the conveying process; in the process of drug release, the drug release effect is good, the utilization rate of the drug is improved, and the quality of vascular interventional therapy is ensured; the first balloon and the fifth balloon are used for adhering floating medicines and carrying out the medicines, so that the risk of blocking blood vessels by the medicines is reduced.

Further, in the inflated state, a side of the first balloon and the fifth balloon adjacent to the third balloon is concave inward. So designed, the balloon catheter is reciprocated in the blood vessel, and the medicine floating between the first balloon and the fifth balloon can be adhered more effectively.

Further, the top surfaces and/or the bottom surfaces of the first balloon and the fifth balloon are provided with a plurality of longitudinal supporting ribs; the supporting ribs are radial skeletons from the center of the balloon to the tail end, so that the strength of the first balloon and the fifth balloon is increased.

Further, the outer surface of the third balloon is provided with a plurality of grooves, and medicines are stored in the grooves.

Further, the liposome is coated on the outer layer of the medicine, so that the targeting and toxicity reduction effects are realized. The liposomes are stored in the grooves. The liposome wraps the drug, so that the stability of the drug is improved, and the loss of the drug in the conveying process is reduced. The liposome can be degraded in vivo, and has high safety.

The third working group further comprises a film coated on the outer surface of the third balloon, and two ends of the film are respectively fixed at two ends of the third balloon, so that the loss of medicines in the process of entering the blood vessel to the target area of the third balloon can be effectively avoided; meanwhile, after the membrane is broken, the end part of the membrane is still connected to the catheter, and the membrane can not move along with blood flow to cause blockage of blood vessels.

Further, the film is provided with a cutting line, and in the process of pressurizing and expanding the third balloon, the film is extruded to burst along the cutting line, so that the medicine on the surface of the third balloon is released.

Further, the third working group further comprises a wire and an ultrasonic element; the ultrasonic element is arranged on the outer wall of the catheter covered by the third balloon and is connected with an external ultrasonic control device through a wire; the guide wire is disposed within the catheter and extends to the proximal end of the catheter. Through the ultrasonic effect, the medicine on the surface of the third saccule can be more effectively released to the vascular wall, and meanwhile, plaque on the vascular wall receives the cavitation effect of ultrasonic, and is broken into small blocks to fall off from the vascular wall, so that the effect of cleaning the vascular wall is achieved.

For a better understanding and implementation, the present utility model is described in detail below with reference to the drawings.

Drawings

FIG. 1 is a schematic structural diagram of an embodiment of the present application;

FIG. 2 is a schematic diagram of a second working group;

FIG. 3 is a schematic view of the internal structure of a catheter;

FIG. 4 is a schematic view of the proximal end of the catheter;

FIG. 5 is a schematic view of the structure of the third balloon when it is not fully inflated;

FIG. 6 is a schematic illustration of a third balloon contracted state;

FIG. 7 is a second schematic illustration of a third balloon contracted state;

FIG. 8 is a schematic view of a film cut line.

In the figure: vessel wall-100; drug-200; guidewire-300; a catheter-10; a first workgroup-21; a first interface-211; a first chamber-212; a second workgroup-22; a second interface-221; a second chamber-222; first balloon-223; fifth balloon-224; a third working group-23; a third interface-231; a third chamber-232; a third balloon-233; balloon body-2331; balloon valve-2332; groove-2333; film-234; cut line-2341; an ultrasonic element-235; wire-236; fourth workgroup-24; a fourth interface-241; fourth chamber-242; a second balloon-243; fourth balloon-244; tip-30.

Detailed Description

The following description of the embodiments of the present utility model will be made clearly and completely with reference to the accompanying drawings, in which it is apparent that the embodiments described are only some embodiments of the present utility model, but not all embodiments. All other embodiments, which can be made by those skilled in the art based on the embodiments of the utility model without making any inventive effort, are intended to be within the scope of the utility model.

In the description of the present utility model, it should be noted that the azimuth or positional relationship indicated by the terms "vertical direction", "upper", "lower", "horizontal", etc. are based on the azimuth or positional relationship shown in the drawings, and are merely for convenience of describing the present utility model and simplifying the description, and do not indicate or imply that the apparatus or element in question must have a specific azimuth, and are constructed and operated in a specific azimuth, and thus should not be construed as limiting the present utility model. Furthermore, the terms "first," second, "" third, "" fourth, "and fifth" are used for descriptive purposes only and are not to be construed as indicating or implying relative importance.

In the description of the present utility model, it should also be noted that, unless explicitly specified and limited otherwise, the terms "disposed," "mounted," "connected," and "connected" are to be construed broadly, and may be, for example, fixedly connected, detachably connected, integrally connected, mechanically connected, electrically connected, directly connected, connected via an intermediary, or connected by communication between two elements. The term "proximal" generally refers to the end of the corresponding member that is proximal to the operator and "distal" refers to the end of the corresponding member that is distal to the operator. The specific meaning of the above terms in the present utility model can be understood by those of ordinary skill in the art according to the specific circumstances.

Referring to fig. 1-4, a drug balloon catheter provided in this embodiment includes: catheter 10, a working assembly (not shown) and a tip 30 disposed at the distal-most end of catheter 10.

The working assembly comprises a first working group 21, a second working group 22, a third working group 23 and a fourth working group 24 arranged inside/outside the catheter 10.

The first workgroup 21 includes a first interface 211 and a first cavity 212. The first interface 211 is connected to the first cavity 212; the first port 211 is disposed at the proximal end of the catheter 10; the first lumen 212 is disposed within the catheter 10; the guidewire 300 penetrates the first lumen 212.

The second working group 22 includes a second interface 221, a second lumen 222, a first balloon 223, and a fifth balloon 224. The second interface 221 is a pressure-filling opening of the first balloon 223 and the fifth balloon 224, and is arranged at the proximal end of the catheter 10; the second lumen 222 is disposed within the catheter 10; one end of the second cavity 222 is connected with the second interface 221, and the other end is sequentially connected with the first balloon 223 and the fifth balloon 224. The first balloon 223 and the fifth balloon 224 cover the catheter 10 and are disposed outside the catheter 10. Specifically, two holes are formed in the catheter and are respectively communicated with the first balloon 223 and the fifth balloon 224, the pressure is relieved through the second interface 221, and the first balloon 223 and the fifth balloon 224 are simultaneously expanded or contracted.

The third working group 23 includes a third interface 231, a third lumen 232, and a third balloon 233. The third interface 231 is a pressure filling opening of the third balloon 233 and is arranged at the proximal end of the catheter 10; one end of the third lumen 232 is connected to the third interface 231 and the other end is connected to the third balloon 233. The third balloon 233 is wrapped around the catheter 10 and disposed outside the catheter 10. The drug 200 is loaded on the outer surface of the third balloon 233. Specifically, the hole on the catheter is communicated with the third balloon 233, the pressure is relieved through the third port 231, and the third balloon 233 is expanded or contracted.

Fourth working group 24 includes a fourth interface 241, a fourth lumen 242, a second balloon 243, and a fourth balloon 244. Fourth interface 241 is a pressure-filling port of second balloon 243 and fourth balloon 244, disposed at the proximal end of catheter 10; one end of the fourth cavity 242 is connected with the fourth interface 241, and the other end is sequentially communicated with the second balloon 243 and the fourth balloon 244. The second balloon 243 and the fourth balloon 244 cover the catheter 10, and are disposed outside the catheter 10. Specifically, two holes are provided on the catheter to communicate with the second balloon 243 and the fourth balloon 244, respectively, and the pressure is relieved through the fourth interface 241, and the second balloon 243 and the fourth balloon 244 are simultaneously inflated or deflated.

Referring to fig. 3, the first chamber 212, the second chamber 222, the third chamber 232 and the fourth chamber 242 are disposed within the catheter 10 in isolation from each other.

Referring to fig. 1, the first balloon 223, the second balloon 243, the third balloon 233, the fourth balloon 244 and the fifth balloon 224 are sequentially coated and disposed outside the catheter 10.

The surfaces of the first balloon 223 and the fifth balloon 224 are coated with an adhesive; the adhesive may be a phospholipid, cholesterol or fatty acid. The adhesive is used for adhering drugs or plaque floating in blood, thrombus, etc.

After the first balloon 223 and the fifth balloon 224 are inflated, the first balloon 223 and the fifth balloon 224 are in a symmetrical umbrella shape. The maximum cross-sectional diameters of the first balloon 223 and the fifth balloon 224 are smaller than the diameter of the blood vessel. In this embodiment, in order to ensure that the first balloon 223 and the fifth balloon 224 are not deformed when reciprocally moving in the blood vessel in the pressurized state, a plurality of longitudinal support ribs may be provided on the top surface or the bottom surface of the balloon so as to have a certain strength. The support ribs may be a framework which is radial from the center of the balloon to the end.

In the present embodiment, the first balloon 223 and the fifth balloon 224 are umbrella-shaped in order to facilitate adhesion of drugs and plaque in blood during the reciprocal movement of the first balloon 223 and the fifth balloon 224 in the blood vessel, and are not a limitation on the outer shape of the first balloon 223 and the fifth balloon 224. In other embodiments, the first balloon 223 and the fifth balloon 224 may be symmetrically disposed cylinders, cones, or other shapes recessed toward each other to facilitate adhesion of drugs and plaque.

The second balloon 243 and the fourth balloon 244 are symmetrically arranged between the first balloon 223 and the fifth balloon 224, the second balloon 243 and the fourth balloon 244 are pressurized, the second balloon 243 and the fourth balloon 244 can be directly contacted with the vessel wall 100 after being pressurized, a sealed interval is formed, the sealed interval is used for temporarily sealing the blood vessel, and the scouring of blood flow to the medicine is prevented in the medicine release process.

Referring to fig. 5, a third balloon 233 is disposed between the second balloon 243 and the fourth balloon 244. The outer surface of the third balloon 233 is provided with a groove 2333; the medicament is stored in the recess 2333. It will be appreciated that, to ensure that the drug does not run off during the time that the balloon catheter is entering the blood vessel, a membrane 234 may be applied to the exterior of the third balloon 233, the membrane 234 acting to isolate the drug from the blood. When the third balloon 233 reaches the vascular lesion site, the third balloon 233 is pressurized, the third balloon 233 is inflated, the membrane 234 bursts, the third balloon 233 is inflated against the vessel wall 100, and the drug is released onto the vessel wall 100.

Referring to fig. 6, the third balloon 233 is loaded with drug particles on its outer surface. When the third balloon 233 is in a contracted state, the balloon body 2331 and the plurality of balloon valves 2332 circumferentially wrapped on the balloon body 2331 are formed in a folded manner, and a part of the medicine is clamped between the balloon valves 2332. When the third balloon 233 is pressurized, the balloon valve 2332 is expanded and expanded, and the third balloon 233 has a balloon shape with a circular cross section, so that the medicine on the outer surface of the third balloon 233 can be entirely exposed so as to be able to contact the vessel wall. It will be appreciated that when the third balloon 233 is in the contracted state, since a portion of the drug is hidden between the balloon valves 2332, the drug balloon catheter may protect the drug during intravascular delivery, which may facilitate further reduction of drug loss.

The folded state diagram of the third balloon 233 shown in fig. 6 does not limit the contracted state structure of the third balloon 233.

Referring to fig. 7, in other embodiments, in the folded state of the third balloon 233, the balloon valves 2332 may also have two ends extending reversely along the circumferential direction of the third balloon 233.

Referring to fig. 8, it can be understood that, in order to ensure that the drug can be uniformly released onto the vessel wall 100 or the membrane 234 is more easily burst, a cutting line 2341 is provided on the membrane 234, the third balloon 233 is pressurized, the third balloon 233 is inflated, and the membrane 234 is uniformly ruptured along the cutting line 2341 after being pressed outward by the third balloon 233, so that the third balloon 233 can be more fully contacted with the vessel wall 100, thereby enabling the drug to be more effectively contacted with the vessel wall 100 and improving the use efficiency of the drug. Note that, the cutting line 2341 may be any shape that facilitates the film 234 to be uniformly broken by force, and the cutting line 2341 in this embodiment does not limit the shape of the cutting line 2341. After the membrane 234 is ruptured, the end of the membrane 234 remains attached to the catheter and does not move with the blood flow.

In order to further improve the use efficiency of the drug, the liposome prepared from lecithin, ceramide and the like is used as a drug carrier for encapsulating the drug, so that the drug has the effects of achieving targeting and reducing toxicity. The liposome has a bilayer structure identical to the tissue cell membrane structure. The liposome wraps the drug, so that the stability of the drug is improved, and the loss of the drug in the conveying process is reduced. The liposome can be degraded in vivo, and has high safety. Related studies indicate that: the lipid can increase tissue permeability, has slow release effect, and reduces toxicity of liposome-encapsulated drug by 50-70% compared with free drug. The liposome surface can modify the ligand of the related receptor, guide the active targeting of the drug-containing liposome to a specific position, and improve the concentration of the drug in the focus area.

In this embodiment, the liposome may be selected from the group consisting of a lipid nanoparticle, a multivesicular liposome, a temperature-sensitive liposome, an immunoliposome, a long circulating liposome, a pH liposome, a magnetic liposome, a membrane fusion liposome, or a flexible liposome. It will be appreciated that other types of liposomes may be used.

Further, in order to promote the release and absorption of the drug, in this embodiment, a plurality of ultrasonic elements 235 are disposed on the outer wall of the catheter 10 covered by the third balloon 233, and the ultrasonic elements 235 are electrically connected to an external ultrasonic control device (not shown in the figure) through wires 236.

Specifically, the plurality of ultrasonic elements 235 are oriented in different directions and are disposed on the outer wall surface of the catheter 10 at intervals, so that the overall configuration of the ultrasonic elements 235 is annular or cylindrical, and ultrasonic waves are respectively emitted in different directions and act on the whole peripheral vascular wall.

Specifically, one end of wire 236 is electrically connected to an external ultrasound control device; the other end extends through the wall of the catheter 10 into the third balloon 233 and is electrically connected to the ultrasonic element 235. In other embodiments, it may be fixed to the inner wall of the third chamber 232.

The ultrasonic element 235 is operable to emit ultrasonic waves directed against the drug on the surface of the third balloon 233, allowing the drug to be released on the outer surface of the third balloon 233. Meanwhile, under the action of ultrasonic waves, the vascular wall 100 and tissues can accelerate the absorption of the medicine, and the medicine utilization rate is improved. Further, the ultrasonic wave simultaneously acts on the thrombus lesion on the vessel wall 100, and pulse action is carried out on the calcified area, so that the calcified area can be shattered, cracks are formed, even calcium deposit is shattered (ultrasonic lithotripsy principle), the plaque is broken into small blocks due to the ultrasonic action and falls off from the vessel wall 100 into the vessel, and the effective same-line sectional area of the vessel is enlarged.

The ultrasonic control device controls the operation state of the ultrasonic element 235, such as start and stop of the operation of the ultrasonic element 235, the frequency of emitting ultrasonic waves, the operation voltage, and the like. The ultrasonic power range is 0.4-15W/cm ^-2 The ultrasonic frequency range is 0.02-3.4MHz.

The tip 30 is a tapered member disposed adjacent the forward-most end of the fifth balloon 224 and is effective to avoid damaging the blood vessel as it is advanced therein.

In the embodiment of the present application, in order to show the positions of the respective balloons, developing members (not shown in the drawings) are provided on the catheters inside the first balloon 223, the second balloon 243, the third balloon 233, the fourth balloon 244, and the fifth balloon 224. In other embodiments, the developing members are provided at both ends of the first balloon 223, the second balloon 243, the third balloon 233, the fourth balloon 244, and the fifth balloon 224, respectively. When the drug balloon catheter enters the blood vessel, the operator can accurately position the position of each balloon through the developable member. It should be noted that the meaning of development is that a black image, mainly an X-ray opaque material, can be displayed at the time of imaging in hospital instruments. The developing part is made of gold, platinum iridium, barium salt, bismuth salt, tungsten salt, metal barium, metal tungsten, metal bismuth or alloy and the like.

The application method of the drug balloon catheter provided by the embodiment is as follows:

in a first step, after successful percutaneous puncture, the guidewire 300 is delivered to the target region of the vessel, followed by a drug balloon catheter along the guidewire 300 to the target region.

In a second step, the fourth working group 24 is operated, the fourth lumen 242 is pressurized through the fourth port 241, and the second balloon 243 and the fourth balloon 244 are inflated, so that the second balloon 243 and the fourth balloon 244 are closely attached to the vessel wall 100 of the target area, forming a closed space.

In the third step, the third working group 23 works, the third lumen 232 is pressurized through the third port 231, the third balloon 233 is inflated, the film 234 coated on the outside of the third balloon 233 is ruptured along the cutting line 2341, and the drug-coated liposome stored in the groove 2333 on the outer surface of the third balloon 233 is released from the third balloon 233. The third balloon 233 is inflated to an outer surface against the vessel wall 100, causing the drug-entrapped liposomes to adhere to the vessel wall 100. During this process, small amounts of liposomes fall off and float in the blood. At the same time, the ultrasound control device is turned on to perform ultrasound according to the set ultrasound time and ultrasound frequency, promoting adhesion of the liposome to the vessel wall 100. At the same time, plaque on the vessel wall 100 breaks up due to cavitation of ultrasound, and falls off the vessel wall 100 to float in the blood.

Fourth, the second working group 22 is operated, the second lumen 222 is pressurized through the second port 221, and the first balloon 223 and the fifth balloon 224 are inflated to a set shape. The second, third and

fourth balloons

243, 233 and 244 are then depressurized, and the second, third and

fourth balloons

243, 233 and 244 are contracted. The catheter 10 is then pulled back and forth in the blood vessel, allowing the first balloon 223 and the fifth balloon 224 to adequately adhere to the liposomes and plaque in the blood.

Fifth, after the first balloon 223 and the fifth balloon 224 are adhered with the liposome and the plaque in the blood, the first balloon 223 and the fifth balloon 224 are decompressed, the first balloon 223 and the fifth balloon 224 are contracted, and the adhered liposome and plaque are wrapped inside the umbrella surface of the first balloon 223 and the fifth balloon 224.

Sixth, the drug balloon catheter is withdrawn from the body along the guide wire 300, and the liposomes and plaque in the blood are carried out of the blood vessel, and then hemostasis by compression or suture is performed, thereby completing the interventional therapy.

Compared with the prior art, the drug balloon catheter provided by the utility model has the beneficial effects that:

1. the second balloon and the fourth balloon are tightly attached to the wall of the blood vessel to form a closed interval for temporarily blocking blood flow, and when the third balloon releases the medicine, the medicine cannot be lost along with the flow of the blood, so that the utilization rate of the medicine is improved.

2. The third saccule is assisted by ultrasonic loading to release the medicine, so that the release speed of the medicine is accelerated, and meanwhile, the plaque on the vascular wall is broken and falls off from the vascular wall through cavitation of the ultrasonic, so that the risk of vascular blockage is reduced.

3. And a layer of film provided with cutting lines is coated outside the third balloon, so that the medicine stored on the outer surface of the third balloon is prevented from losing in the process of entering a blood vessel to reach a target area, and the utilization rate of the medicine is improved.

4. The first balloon and the fifth balloon are used for adhering the medicine, plaque or thrombus floating in blood and taking out of the body, so that the effects of recovering the medicine and cleaning the blood vessel are achieved, the quality of vascular interventional therapy is ensured, and the risk of blocking the blood vessel by the medicine is reduced.

The above examples illustrate only a few embodiments of the utility model, which are described in detail and are not to be construed as limiting the scope of the utility model. It should be noted that modifications and improvements can be made by those skilled in the art without departing from the spirit of the utility model, and the utility model is intended to encompass such modifications and improvements.

Claims

1. A drug balloon catheter, comprising: a catheter, a working assembly, and a tip disposed at a distal-most end of the catheter;

the working assembly comprises a first working group, a second working group, a third working group and a fourth working group;

the first workgroup includes a first interface and a first cavity; the first interface is arranged at the proximal end of the catheter; the first interface is connected with the first cavity; the first cavity is arranged inside the catheter and is used for passing through a guide wire;

the third working group comprises a third interface, a third cavity and a third balloon; the third interface is arranged at the proximal end of the catheter; the third balloon is sleeved outside the catheter; drug is loaded on the outer surface of the third balloon; one end of the third cavity is connected with a third interface, and the other end of the third cavity is communicated with the third balloon;

the second working group comprises a second interface, a second cavity, and a first balloon and a fifth balloon with surfaces coated with adhesive; the second interface is arranged at the proximal end of the catheter; the first balloon and the fifth balloon are respectively arranged on two sides of the third balloon, and the first balloon and the fifth balloon are sleeved outside the catheter; one end of the second cavity is connected with a second interface, and the other end of the second cavity is sequentially communicated with the first balloon and the fifth balloon;

the fourth working group comprises a fourth interface, a fourth cavity, a second balloon and a fourth balloon; the fourth interface is arranged at the proximal end of the catheter; the second balloon and the fourth balloon are sleeved outside the catheter; the second balloon is arranged between the first balloon and the third balloon; the fourth balloon is arranged between the third balloon and the fifth balloon; one end of the fourth cavity is connected with a fourth interface, and the other end of the fourth cavity is sequentially communicated with the second balloon and the fourth balloon;

2. A drug balloon catheter according to claim 1 and wherein: in the inflated state, a side of the first balloon and the fifth balloon adjacent to the third balloon is concave inward.

3. A drug balloon catheter according to claim 2 wherein: the top surfaces and/or the bottom surfaces of the first balloon and the fifth balloon are provided with a plurality of longitudinal supporting ribs.

4. A drug balloon catheter according to claim 3 wherein: the outer surface of the third balloon is provided with a plurality of grooves, and medicines are stored in the grooves.

5. A drug balloon catheter according to claim 4 and wherein: the drug outer layer is wrapped with liposome, and the liposome is stored in the groove.

6. A drug balloon catheter according to claim 5 and wherein: the third working group further comprises a film coated on the outer surface of the third balloon, and two ends of the film are respectively fixed at two ends of the third balloon.

7. A drug balloon catheter according to claim 6 and wherein: the film is provided with cutting lines.

8. A drug balloon catheter according to any of claims 1-7 and wherein: the third working group further comprises a wire and an ultrasonic element; the ultrasonic element is arranged on the outer wall of the catheter covered by the third balloon and is connected with an external ultrasonic control device through a wire; the guide wire is disposed within the catheter and extends to a proximal end of the catheter.